BPC-157: the benefits claimed, the human evidence and the new HHS policy

BPC-157 has no proven benefit in people, and it is not FDA-approved for anything. The enthusiasm comes from three decades of rat studies, mostly from one laboratory in Zagreb, showing faster healing of tendon, muscle, ligament and gut. The human record is five small studies, and none of them tested the ways most people use it, which are an injection under the skin or a capsule. If you are weighing it up, read BPC-157 side effects next, then BPC-157 dosage, which explains why no human dose exists.

What is BPC-157?

BPC-157 is a chain of 15 amino acids (Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val), which makes it a pentadecapeptide. It is a partial sequence of a larger protein called Body Protection Compound, isolated from human gastric juice, and you may also see it called Bepecin or PL-14736. What circulates today is made synthetically. It resists breakdown in stomach acid, which is unusual for a peptide and is why the original researchers tried it both by injection and by mouth.

Two forms exist, the free base and the acetate salt, and FDA treats them as different bulk substances. The distinction matters now, because the HHS policy names only the acetate.

How is BPC-157 supposed to work?

Nobody has pinned it down. Researchers have proposed that it raises growth factors and their receptors, dampens inflammatory signals, encourages new blood vessels (angiogenesis) and stimulates nitric oxide. FDA’s July 2026 review said the molecular targets “have not been identified” and that the mechanisms “remain poorly understood,” which made it hard to judge whether the rat results are biologically plausible.

What are the benefits of BPC-157?

No benefit of BPC-157 has been established in people. Every benefit you will read about traces back to animal work or to a small human study with no comparison group.

These are the animal studies people cite most, with what was done in each.

Taken together, they show a repeatable effect in rats and rat cells, which is a fair reason for scientific interest. They do not show the same thing happens in a person. Most of the positive studies come from a single group, FDA noted that dose-response relationships have not been established, and a 2025 review noted that every published human study reports a positive result, which raises the possibility of publication bias.

What do the human studies show?

FDA’s review found five clinical studies. Read the middle column closely, because none of these is how BPC-157 is usually used.

FDA called the colitis abstract “inadequate to support the efficacy and safety” of BPC-157. A 2026 systematic review in Acta Orthopaedica Belgica looked at the three clinic studies, judged all of them poor quality, rated the certainty of evidence very low, and concluded that BPC-157 “should not be used clinically in humans outside ethically approved, regulated, high-quality clinical trials.” A 2025 narrative review reached a similar view, and a 2026 American Journal of Sports Medicine review said the knee study had “significant methodological flaws.”

Two more entries belong here. A phase 1 oral study registered in 2015 (NCT02637284) planned to give tablets to 42 healthy volunteers in Mexico, but no results have been posted and FDA could not find a publication. A University of Arkansas pilot in people recovering from rotator cuff surgery (NCT07803250) is listed as not yet recruiting, with a planned start in January 2027.

How long does BPC-157 take to work?

Nobody can say, because no controlled study has measured it in people. A preprint reported by AJMC in October 2026 searched more than 15 million medical records and found 1,039 people with documented use. Of the 354 whose response was recorded, 79% reported improvement. That sounds encouraging until you see what is missing: there was no placebo or untreated comparison, no standard dose or formulation, and about half of users were taking something else as well. The same analysis recorded people stopping because of clinician advice or adverse events. It has not been peer reviewed.

Is BPC-157 safe?

Its safety in people is unknown. The small studies reported no serious adverse events, but they were short, and FDA said the authors gave limited safety information. FDA concluded there is “insufficient clinical safety information to characterize the safety profile.” Animal toxicology turned up possible clotting and liver signals, and no one has run a cancer study. FDA’s largest stated worry for injected BPC-157 is immunogenicity, meaning an immune reaction against the peptide. The BPC-157 side effects guide sets out each report and the red flags.

FDA status and the October 2026 HHS policy

BPC-157 has never had a New Drug Application. The only process it has been through concerns the bulk substances that pharmacies may use under section 503A of the Food, Drug, and Cosmetic Act.

What the policy does

As of November 2, 2026, HHS says it does not intend to take enforcement action against a state-licensed pharmacy, federal facility or licensed physician compounding BPC-157 when all ten conditions are met, until a final rule decides whether it goes on the 503A bulks list. It came from the Secretary’s office, and HHS says one aim is to discourage use of research-use-only peptides from foreign manufacturers. The main conditions for BPC-157 are:

• The acetate form with the sequence HHS specifies, for injection under the skin or into muscle, oral or topical use.
• A bulk substance from an FDA-registered, CGMP-compliant manufacturer, with a valid certificate of analysis.
• One active ingredient per product, so blends are out.
• A valid patient-specific prescription.
• Reporting of serious adverse events and quality problems to FDA MedWatch and the states involved.
• For oral products, documentation that the formulation reaches adequate bioavailability in humans.

What the policy does not do

• It does not make BPC-157 FDA-approved, and FDA has not reviewed any compounded product for safety, effectiveness or quality.
• It does not put BPC-157 on the 503A bulks list. No rule has been proposed.
• It creates no rights. The notice says it is “not binding on HHS or the public,” calls itself a draft in places, and says HHS may revisit it if a safety signal or quality problem appears.
• It covers 503A compounding only, so outsourcing facilities (503B) are outside it.
• It does not bind states, which can be stricter.
• It changes none of the evidence. HHS’s own statement stresses that it does not establish safety or effectiveness.

FDA staff and HHS read the same record differently. FDA’s reviewers concluded that BPC-157 is not well characterized and proposed against listing it. HHS’s appendix cites newly submitted certificates of analysis, documented use and the policy’s safeguards. Public Citizen urged HHS to rescind the policy, and a viewpoint in JAMA from researchers at the Center for Science in the Public Interest argued that listing would undermine the drug approval process.

What research use only means

The phrase comes from 21 CFR 312.160, which lets a company ship an unapproved drug only for tests in laboratory animals or in test tubes, with a label reading “Not for use in humans.” A vial sold to an individual through a consumer website does not fit that rule, and FDA warning letters in 2024 and 2026 found the sellers’ own marketing showed the products were meant for people. Research-use-only BPC-157 is not legal to use on people, and the HHS policy gives it no cover. The policy’s certificate requirements exist because of what such products can contain.

How does BPC-157 compare with approved treatment?

There is no head-to-head study of BPC-157 against anything. For ulcerative colitis, the use FDA reviewed, the agency lists many approved options, from mesalamine to biologic drugs, and says the available data do not support BPC-157 in that disease. For a sports injury, NIAMS describes rest, ice, compression and elevation for many injuries, physical therapy for more severe ones, and surgery in some cases, with exercise-based rehabilitation before returning to activity. A peptide with no human efficacy data is not a like-for-like alternative to any of these. Its usual partner is TB-500, and the BPC-157 and TB-500 guide covers the pair.

Oral versus injectable claims

Sellers market capsules and injectable vials side by side and imply similar results. The rat work did use oral dosing, usually in drinking water, in gut-injury models. FDA found no human study of either route and no human absorption data after oral dosing. HHS’s own testing appendix refers to the “low oral bioavailability” of peptides, and the policy expects anyone compounding an oral form to hold evidence that it is absorbed. The BPC-157 capsules guide goes through what that means for supplement-style products.

Cost and access

This site does not list sellers, clinics or prices for BPC-157, and we are not suggesting anyone seek it out. Being tolerated under an enforcement policy is a long way from being shown to help.

Is BPC-157 banned in sport?

Yes. WADA added BPC-157 by name to class S0, non-approved substances, in the 2022 Prohibited List. S0 substances are prohibited at all times, in and out of competition, and the current List still names it. A compounding policy in the United States has no bearing on anti-doping rules.

Questions to ask a prescriber

If a clinician brings up BPC-157, these questions show quickly how carefully it is being handled:

• What is this meant to treat, and what evidence do you have for that in people?
• Which approved or better-studied options have we not tried?
• Is this a single-peptide product compounded for me by a state-licensed pharmacy, and does our state permit it?
• Can the pharmacy show the certificate of analysis and name the original manufacturer?
• How will you decide whether it is helping, and when will we stop?
• Who do I call if I react to it, and how is that reported to FDA?

Who has the most reason for caution

There is no FDA label, so there is no official list of contraindications. Nobody has been shown to benefit, and the groups below are where the missing data matter most. This is our reading of FDA’s review and of who the registered trials excluded.

• Pregnancy or breastfeeding. Both registered studies exclude these groups. A single rat study looked at fetal development, and no study covered a full reproductive cycle.
• A history of cancer. No carcinogenicity study exists, and BPC-157 is proposed to encourage new blood vessels.
• Bleeding disorders or blood thinners. Clotting times shifted in animals, shorter in rats and longer in dogs.
• Liver disease. Liver-related changes appeared in female rats.
• Autoimmune disease. The Arkansas pilot excludes it, and immune reactions are FDA’s main concern with injected peptides.
• Tested athletes. A positive test carries a ban.